Overview
Subscribe
VC Statistics
Back to VC Home
MedTRACK
MedTRACK Japan
Report Center

 
Venture Finance Statistics

Our Venture Finance Database, which includes many of the Life Science Venture Financing transactions over the last fifteen years, is updated on a daily basis. We rely on annual reports, regulatory filings, press releases, articles, websites and company contacts to source this information. Venture finance is subject to timing and we combine the most up-to-date information with the ability to gain a historical perspective by searching the database. We have summarized Venture Financing Rounds for your convenience and will continue to update them as our database expands.

Top 15 Investment Firms in 2009 based on Rounds of Financing
Firm NameRoundsCapital Amount
(USD Millions)
Novartis Venture Funds21650
Kleiner Perkins Caufield & Byers202700
New Enterprise Associates, Inc. (NEA)208500
Versant Venture Management LLC191600
SV Life Sciences (formerly Schroder Ventures Life Sciences)181500
Polaris Venture Partners183000
Domain Associates, L.L.C.162500
Novo A/S16--
Texas Coalition for Capital16--
InterWest Partners LLC152800
MPM Capital152000
Pittsburgh Life Sciences Greenhouse15--
Abingworth Management Limited141250
Johnson & Johnson Development Corporation14--
GrowthWorks Capital, Ltd.13655

Top 15 Investment Raised Companies during 2009
Company NameAmount Raised
(USD Millions)
Crucell N.V.443.52
Clovis Oncology, Inc.145
Small Bone Innovations, Inc.73
Amarin Corporation plc70
Pacific Biosciences, Inc.68
Hyperion Therapeutics, Inc.60
Sopherion Therapeutics, Inc.55
TransEnterix, Inc.55
NovImmune SA54.8
Probiodrug AG53
Anacor Pharmaceuticals, Inc.50
PTC Therapeutics, Inc.50
Xanodyne Pharmaceuticals, Inc. (formerly Xanodyne Pharmacal)50
Calypso Medical Technologies, Inc.50
PhotoThera50





 
 
Current Statistics
Total Transactions12506
Total Companies5105
Total Firms5666

800 James Ave.
Suite 201
Scranton, PA 18510

If you would like immediate response, you may contact directly.
Telephone:
570-504-1800
email: info@medtrack.com



 
The information contained herein is based on sources believed to be reliable but is neither all-inclusive nor guaranteed by Life Science Analytics ("LSA"). Opinions, if any, reflect the judgment of LSA at this time and are subject to change. LSA does not undertake to advise you of changes in their opinion or information. Most of the companies LSA follows are emerging growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in the reports included in LSA's Database may be unsuitable for investors depending on their specific investment objectives, financial situation and needs. No report included in the LSA Database is a recommendation that any particular investor should purchase or sell any particular security in any amount or at all, and is not a solicitation of any offer to purchase or sell from or to any particular investor. For additional information that may be available on the securities mentioned, please contact Life Science Analytics.